Drug Shortage Report for TEVA-LISINOPRIL/HCTZ (TYPE Z)
Report ID | 97625 |
Drug Identification Number | 02301776 |
Brand name | TEVA-LISINOPRIL/HCTZ (TYPE Z) |
Common or Proper name | LISINOPRIL/HCTZ Z |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE LISINOPRIL |
Strength(s) | 12.5MG 20MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 30's & 100's |
ATC code | C09BA |
ATC description | ACE INHIBITORS, COMBINATIONS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2019-11-01 |
Actual start date | 2020-04-01 |
Estimated end date | 2020-09-30 |
Actual end date | 2020-09-23 |
Shortage status | Resolved |
Updated date | 2020-09-24 |
Company comments | Will cover 25% of the market throughout shortage period. Due to competitor shortage. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2019-11-02 | English | Compare |
v2 | 2019-10-31 | French | Compare |
v1 | 2019-10-31 | English | Compare |